Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYJXV7)

• Drug Name: [3H]5-HT Drug Info
• Synonyms: [3H]-5-HT

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 53317992
  TTD Drug ID: DMYJXV7

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[6]
Eletriptan	DMW649X	Migraine	8A80	Approved	[7]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[7]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[7]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[8]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[9]
Almogran	DM7I64Z	Migraine	8A80	Approved	[10]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[11]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[12]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[13]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[14]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[15]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[16]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[17]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[18]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[19]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[20]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[20]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[20]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[20]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[12]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[21]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[22]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[23]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[24]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[24]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[25]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[25]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[26]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[27]

Drug(s) Targeting 5-HT 1E receptor (HTR1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[28]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[28]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[28]
1-naphthylpiperazine	DM6BIWK	Discovery agent	N.A.	Investigative	[28]
BRL-15572	DMM61Y2	Discovery agent	N.A.	Investigative	[29]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[30]
alpha-methyl-5-HT	DMCAYXF	Discovery agent	N.A.	Investigative	[28]
m-chlorophenylpiperazine	DMM1J2D	Discovery agent	N.A.	Investigative	[28]
EDMT	DMS3AXK	Discovery agent	N.A.	Investigative	[31]
9-OH-risperidone	DMGORXQ	Discovery agent	N.A.	Investigative	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[2]
5-HT 1E receptor (HTR1E)	TTCPG9S	5HT1E_HUMAN	Agonist	[3]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Agonist	[4]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Agonist	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3248).
• [2] Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
• [3] Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.
• [4] Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
• [5] Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6.
• [6] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [9] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [10] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [11] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Company report (NeurAxon)
• [14] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [15] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [16] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [17] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [18] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [19] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [20] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [21] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [22] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [23] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [24] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [25] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [26] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [27] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [28] Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
• [29] SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
• [30] Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
• [31] 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
• [32] Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.